Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PKLR | P30613 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3985932 | 0.90 | P2RX7 (0.31) | — | |
| SCHEMBL3982288 | 0.89 | PKM (0.34) | PKMPKLRTMEM97SIGMAR1KCNH2 | |
| SCHEMBL3982580 | 0.87 | CYP2C9 (0.34) | PKMPKLRTMEM97SIGMAR1KCNH2 | |
| SCHEMBL3982269 | 0.87 | PDE2A (0.37) | PKMPKLRPDE2APDE1BPDE4D | |
| SCHEMBL3985287 | 0.86 | POLB (0.34) | PKMPKLRTMEM97SIGMAR1MAPT | |
| SCHEMBL1384348 | 0.85 | PKM (0.36) | PKMPKLRPDE2APDE1BPDE4D | |
| SCHEMBL3983836 | 0.84 | PKM (0.39) | PKMPKLRTMEM97SIGMAR1KCNH2 | |
| SCHEMBL3984969 | 0.84 | PKM (0.38) | PKMPKLRTMEM97SIGMAR1KCNH2 | |
| SCHEMBL3985422 | 0.84 | PKM (0.36) | PKMPKLRPDE2APDE1BPDE4D | |
| SCHEMBL3983532 | 0.83 | PKM (0.44) | PKMPKLRTMEM97SIGMAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756114-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | claimed |
| US-7538112-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-05-26 | — | — | US | claimed |
| EP-1797065-A4 | ACYCLIC 1,3-DIAMINES AND USES THEREFOR | SMITHKLINE BEECHAM CORP (US) | 2009-03-04 | — | — | EP | claimed |
| US-20080287394-A1 | Hiv Integrase Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | claimed |
| EP-1797065-A2 | ACYCLIC 1,3-DIAMINES AND USES THEREFOR | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-20 | — | — | EP | claimed |
| WO-2006029210-A2 | ACYCLIC 1,3-DIAMINES AND USES THEREFOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | claimed |
| EP-1756114-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287394-A1 | Hiv Integrase Inhibitors | DHPS, DPYD, TYMP | PKM 1268/4885PKLR 519/4885PDE2A 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.